CHANDA COPELAND: Open Payments
NPI 1477820769 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,208 in 102 payments from 19 companies in 2025. Trend: 2023 $1,309 · 2024 $1,610 · 2025 $2,208
Food & beverage: $2,208
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 19 | $452 |
| UCB, Inc. | 18 | $225 |
| Organon LLC | 10 | $210 |
| Galderma Laboratories, L.P. | 4 | $210 |
| Amgen Inc. | 4 | $203 |
| ABBVIE INC. | 13 | $153 |
| PFIZER INC. | 5 | $116 |
| Janssen Biotech, Inc. | 3 | $103 |
| GENZYME CORPORATION | 4 | $102 |
| Medimetriks Pharmaceuticals, Inc. | 5 | $98 |
Products named: Bimzelx, NEMLUVIO, OTEZLA, SKYRIZI, COSENTYX, VTAMA, DUPIXENT, CIBINQO.
Industry payments across DC — which companies pay providers there.
